Month: July 2024

At the end of June 2024, the net asset value (NAV) of UAB “Atsinaujinančios energetikos investicijos” including success fee-accrual decreased to EUR 112,755,226 compared to the previously determined NAV at the end of March 2024 which amounted to EUR 114,055,438. The share price including success fee-accrual decreased to EUR 1.9223 compared to the previously determined share price which at the end of March 2024, amounted to EUR 1.9445. The pro-forma internal rate of return (IRR) since inception including success fee-accrual decreased to 8.12% compared to the previously announced IRR of March 2024, which amounted to 9.48%. At the end of June 2024, the NAV excluding success fee accrual decreased to EUR 112,836,039 compared to the previously determined NAV at the end of March 2024, which amounted to EUR 114,996,122. The share price excluding...

CARLSBAD, Calif., July 10, 2024 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it will be participating in the Sixth Annual ASPN Conference sponsored by The American Society of Pain Neuroscience (ASPN) to be held July 11-14, 2024 at the Fontainebleau in Miami Beach, Florida. Aurora will be located at Booth 121. On July 12th, at 10:15 a.m., Aurora Spine will be hosting a product theater debuting investigator-initiated real-world prospective clinical research on SILO TFX and ZIP 51. Pankaj Mehta MD, Steven Falowski MD, and Jason Pope MD will present a comparative analysis from Aurora Spine’s Refine Study, the first multi-center, multi-specialty, randomized control...

POMPANO BEACH, Fla., July 10, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ulcers are a critical health issue and can lead to lower limb amputations, illness and death in diabetic patients. The medical community is constantly seeking new treatments to prevent or lessen these complications and their considerable impact on patients, families, and the healthcare system as a whole. Our clinical team has developed...

GRAND BAIE, MAURITIUS, July 10, 2024 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX)( “Alphamin” or the “Company”), is pleased to provide the following update for the quarter ended June 2024:Record tin production of 4,027 tonnes, up 28% from the prior quarter Tin sales of 3,245 tonnes, with increased tin stocks from the expansion expected to clear in Q3 EBITDA3 guidance of US$54,2m, up 4% from the prior quarterOperational and Financial Summary for the Quarter ended June 20241__________________________________________________________________________________________                          1Information is disclosed on a 100% basis. Alphamin indirectly owns 84.14% of its operating subsidiary to which the information relates. Tin production includes tin produced at Mpama South since 14 May 2024. 2Q2 2024...

BLOOMINGTON, Ill., July 10, 2024 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT Financial”), the holding company for Heartland Bank and Trust Company, today announced that it will issue its second quarter 2024 financial results before the market opens on Monday, July 22, 2024. A copy of the press release announcing the second quarter 2024 financial results and an investor presentation will be made available on the Company’s investor relations website at https://ir.hbtfinancial.com. About HBT Financial, Inc. HBT Financial, Inc., headquartered in Bloomington, Illinois, is the holding company for Heartland Bank and Trust Company, and has banking roots that can be traced back to 1920. HBT Financial provides a comprehensive suite of financial products and services to consumers, businesses, and municipal...

– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the initial results from the patient reported outcome survey conducted during the UNI-OLC-201 pivotal clinical trial. The positive top-line results from the oxylanthanum carbonate (OLC) trial in patients with hyperphosphatemia who have chronic kidney disease on dialysis were reported on June 25, 2024. The patient reported outcomes are being evaluated from a satisfaction questionnaire that was a pre-specified exploratory objective of the study. The...

GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company’s stockholders have voted to approve a proposal to convert BiomX’s outstanding Series X Non-Voting Convertible Preferred Stock (“Series X Preferred Stock”) into shares of BiomX’s common stock. The result of the vote was previously disclosed in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2024. BiomX’s Series X Preferred Stock was issued upon BiomX’s acquisition of Adaptive Phage Therapeutics, Inc. (“APT”) and a concurrent $50 million financing (the “Financing”), which were consummated in March 2024. As a...

ST. JOHN’S, Newfoundland and Labrador, July 10, 2024 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces that effective July 9, Nathaniel Spencer has been appointed Chief Operating Officer of Kraken. Mr. Spencer joined Kraken in August 2021 with the acquisition of PanGeo Subsea, where he was the Vice President of Service Delivery. For the last 18 months, Nat has been the Managing Director of Kraken’s subsea power business. Nat has over 12 years in the marine sector, including founding a subsea inspection business that was sold to Oceaneering in 2016. Greg Reid, Kraken’s President and CEO noted, “I am pleased to promote Nat to the COO role after 3 years at Kraken. Nat’s strength is in driving operational performance, by building strong teams, setting goals, and effectively...

(All reported figures are in US dollars unless otherwise stated) VANCOUVER, British Columbia, July 10, 2024 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that the Company has secured binding commitments totaling over $105 million to fully finance the construction of the Phase II hard rock expansion at its flagship Bomboré Gold Mine. With this financing, the Company’s Board of Directors has approved a positive construction decision for this brownfield expansion. With early works complete, engineering and procurement well-advanced, and major works expected to commence shortly, the Phase II expansion remains on schedule for first gold in late 2025. Financing Package Highlights:$58 million senior secured term loan with Coris Bank International (“Coris Bank”),...